New therapeutic possibilities for various diseases are made possible via mRNA. The adaptability of in vitro transcribed (IVT) mRNA is largely due to its simpler cell-free manufacture, cell cycle-independent performance, and risk-free insertional mutagenesis.
There are more possibilities for tailored medicines due to the simple and rapid mRNA production workflow, such as patient-specific cancer vaccinations or protein replacement for rare diseases.
Workflow is streamlined from gene synthesis to IVT mRNA generation with GenScript’s mRNA production solution. The quality and expression effectiveness of the mRNA are guaranteed by GenScript’s patented production technology, which is optimized for mRNA production.
One-stop solution for all mRNA needs
- Gene synthesis
- mRNA synthesis
- Linearization
- Plasmid preparation
Highlights
Catalog mRNA
The commercially available mRNA has been enhanced with a 5’ cap and polyA tails and is prepared for use in any research project.
Plasmid DNA linearization
High-quality linearized DNA plasmid for more reliable and consistent synthesis of mRNA.
Why GenScript?
Integrated production process
Providing services for the production of mRNA and genes.
Experienced team with optimized production platform
Spend less time and effort creating and generating mRNA.
Quality control and specification
Source: GenScript
| QC |
Item |
Test Method |
Specification |
RUO
Default |
RUO
Upgrade |
Preclinical
Default |
Preclinical
Upgrade |
| Identification |
Appearance |
Visual Inspect |
Clear and free of foreign particles |
✓ |
✓ |
✓ |
✓ |
| RNA Length |
Capillary Electrophoresis |
Target ± 30% |
✗ |
✓ |
✓ |
✓ |
| RNA Length |
Agarose Gel Electrophoresis |
Expected size band detected |
✓ |
✗ |
✗ |
✗ |
| Poly A Length |
Enzyme digestion and CE |
Target ± 30% |
✗ |
✓ |
✓ |
✓ |
| RNA Content |
UV Absorbance |
Target ± 5% |
✓ |
✓ |
✓ |
✓ |
| PH |
pH meter |
Target ± 0.5 |
✓ |
✓ |
✓ |
✓ |
| Buffer Specification |
Client Spec |
N/A |
✓ |
✓ |
✓ |
✓ |
| Purity |
A 260/280 Ratio |
UV Spec |
1.70 ~ 2.30 |
✓ |
✓ |
✓ |
✓ |
| Capping Efficiency |
LC-MS |
≥ 90% |
✗ |
✓ |
✓ |
✓ |
| Size based purity |
Capillary Electrophoresis |
≥ 75% |
✗ |
✓ |
✓ |
✓ |
| Impurity |
Total protein residue |
Nano Orange Assay |
≤ 1% |
✗ |
✗ |
✓ |
✓ |
| Plasmid DNA Residue |
qPCR |
≤ 0.1% |
✗ |
✗ |
✗ |
✓ |
| dsRNA |
Slot-blot |
≤ 1% |
✗ |
✗ |
✓ |
✓ |
| Safety |
Endotoxin |
Semiquantitative |
< 10EU/mg |
✓ |
✓ |
✗ |
✗ |
| Endotoxin |
Quantitative |
< 10EU/mg |
✗ |
✗ |
✓ |
✓ |
| Bioburden |
Sdirect Inoculation |
No Growth after 48 hrs |
✗ |
✗ |
✗ |
✓ |